APA (7th ed.) Citation

IIIBurris, H. A., Flinn, I. W., Patel, M. R., Fenske, T. S., Deng, C., Brander, D. M., . . . Burris, H. A. 3. (2018). Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: An open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncology, 19(4), 486. https://doi.org/10.1016/S1470-2045(18)30082-2

Chicago Style (17th ed.) Citation

IIIBurris, Howard A., et al. "Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: An Open-label, Phase 1, Dose-escalation, First-in-human Study." Lancet Oncology 19, no. 4 (2018): 486. https://doi.org/10.1016/S1470-2045(18)30082-2.

MLA (9th ed.) Citation

IIIBurris, Howard A., et al. "Umbralisib, a Novel PI3Kδ and Casein Kinase-1ε Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukaemia and Lymphoma: An Open-label, Phase 1, Dose-escalation, First-in-human Study." Lancet Oncology, vol. 19, no. 4, 2018, p. 486, https://doi.org/10.1016/S1470-2045(18)30082-2.